<qa>  What type of therapy should have received?- Should have received at least one prior platinum based chemotherapy and an immune checkpoint targeted agent. In addition, subjects with epidermal growth factor receptor EGFR-mutated and anaplastic lymphoma kinase ALK-translocated NSCLC should have received FDA-approved targeted therapies as appropriate. 